Redbiotec announces collaboration with GSK Vaccines

Please login or
register
17.12.2013

Redbiotec announces a collaboration with GSK. This is another addition to an impressive list of partners including Merck and Roche.

Redbiotec AG, the technology leader in virus-like particle vaccines, with a successful track record including pharma customers and partners such as Roche and Merck amongst others, extends its network of partners.

Redbiotec announces a collaboration with GSK vaccines. This is another validation of Redbiotec’s technology platforfm rePAX and a major milestone after already being granted the prestigious Edufluvac project by EU earlier this year. In this collaboration, Redbiotec’s assets and its proprietary technology platform rePAX will be applied in a feasibility study by GSK for an undisclosed indication.

GSK employs more than 99,000 people in over 100 countries. The vaccine business of GSK is one of the largest in the world, with nearly 900 million doses distributed to 170 countries in 2012. The company produces paediatric and adult vaccines to prevent a range of infectious diseases.

Redbiotec is a privately held Swiss Biopharmaceutical Company, founded in 2006 and based in Zurich-Schlieren. The company uses its proprietary rePAX co-expression technology for the efficient generation of multi-component virus-like particles (VLPs) and other protein assemblies. The company entered the field of VLP vaccines in 2008 and currently has a pipeline in the areas of CMV, HPV and Influenza. Besides developing its own prophylactic VLP vaccine pipeline, the company also offers customized solutions in Biologics to selected Partners.

0Comments

More news about

Redbiotec AG

Company profiles on startup.ch

Redbiotec AG

rss